Kornimate/medical-research-clean huggingface dataset:
covid-19: nasal and salivary detection of the sars-cov-2 virus after antiviral mouthrinses

Conditions: COVID19; Mouthwash; Saliva

Summary: given the current lack of effective covid-19 treatment, it is necessary to explore alternative methods to contain the spread of the infection, focusing in particular on its mode of transmission. the modes of person-to-person transmission of sars-cov-2 are direct transmission, such as sneezing, coughing, transmission through inhalation of small droplets, and transmission through contact, such as contact with nasal, oral and eye mucous membranes. sars-cov-2 can also be transmitted directly or indirectly through saliva. the use of antiviral mouthrinses may be used as adjunctive therapy.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of covid-19 infection by the patient's general practitioner and hospital doctor * clinical signs started less than 8 days ago. * virological confirmation * understanding and acceptance of the trial. * written agreement to participate in the trial exclusion criteria: * pregnancy * breastfeeding * inability to comply with protocol * lack of written agreement

Keywords: covid19 sars-cov-2 mouthrinses antiviral bêta-cyclodextrin citrox
efficacy and safety of hrs-1780 tablets and henagliflozin proline tablets in patients with chronic kidney disease

Conditions: Chronic Kidney Disease

Summary: the objective of this study was to evaluate the efficacy of hrs-1780 tablets or henagliflozin proline tablets in patients with chronic kidney disease by evaluating uacr change from baseline to week 13


Eligibility criteria:
inclusion criteria: 1. men and women aged 18-75 years old 2. body mass index (bmi) ≥18.0 and \<50.0 kg/m2 at the screening visit 3. subjects treated with an angiotensin-converting enzyme inhibitor (acei) and/or angiotensin receptor blocker (arb) for at least 3 months without any adjustments to this therapy for at least 4 weeks prior to the screening visit 4. diagnosed with chronic kidney disease, and the estimated glomerular filtration rate (egfr) was ≥30 and \<90 ml/min/1.73 m2 calculated using the ckd-epi formula at the screening visit 5. urinary albumin/creatinine ratio (uacr) was ≥300 and \<3000 mg/g for at least 2 times on different days detected by the local laboratory; at the screening visit 6. hba1c \<9.0% at the screening visit exclusion criteria: 1. a known or suspected allergy to the investigational drug or its components or excipients; 2. receive a potent inhibitor/inducer of cytochrome p450 3a4 (cyp3a4) within 7 days prior to screening; 3. within 4 weeks before screening, the following drugs could not maintain the stable regimen: diabetes drugs, hypertension drugs, non-steroidal anti-inflammatory drugs, endothelin receptor antagonists; 4. receive sglt-2 or sglt-1/2 inhibitors within 4 weeks before screening 5. received glucagon-like peptide-1 receptor agonist (glp-1ra) within 8 weeks before screening 6. received systemic glucocorticoid therapy within 3 months before screening 7. received immunosuppressive drugs or biological agents 8. received any other study drug treatment within 3 months or 5 half-lives prior to screening 9. severe hypertension that was not controlled at screening visit or random visit (systolic blood pressure ≥160 mmhg or diastolic blood pressure ≥100 mmhg), or systolic blood pressure \<90 mmhg 10. have urinary tract infection or/and genital infection at the screening visit or random visit, or have a history of repeated urinary tract infection or/and genital infection 11. diagnosed or suspected polycystic kidney disease, lupus nephritis, anti-neutrophil cytoplasmic antibody (anca) -associated vasculitis, acute glomerulonephritis, bilateral renal artery stenosis; 12. acute kidney injury or dialysis treatment within 6 months before screening 13. received kidney transplant, or plan to receive kidney transplant during the trial
electrosurgical modes for endoscopic submucosal dissection in peroral endoscopic esophageal myotomy

Conditions: Achalasia; Achalasia Cardia

Summary: peroral endoscopic esophagel myotomy (poem) is a third space endoscopy technique that depends on creating a submucosal tunnel to expose the esophageal muscle and eventually perform an esophageal myotomy. submucosal dissection can be performed using numerous electrosurgical modes. spray coagulation has been anecdotally favored by many endoscopists due to its high coagulation power and assumed safety. recently, precisect mode has been developed, it has theoretical advantages of very minimal tissue penetration and minimal to no charring effect. in this trial, the investigators compare the efficacy and safety of both electrosurgical modes in poem procedures.


Eligibility criteria:
inclusion criteria: * patients undergoing poem procedure for any esophageal motility disorder * esophageal motility disorder confirmed by high-resolution manometry and gastroscopy exclusion criteria: * esophageal varices * esophageal neoplasms * non-correctable coagulopathy * failure to provide an informed consent

Keywords: achalasia poem electrosurgery spray coagulation peroralendoscopic esophageal myotomy
cystic fibrosis foundation (cff) biomarkers of exacerbation

Conditions: Cystic Fibrosis

Summary: clinical and translational research in cystic fibrosis (cf) is hampered by a lack of biomarkers that can be used to identify promising new therapies. there is an urgent need for development and validation of biomarkers that more quickly predict the usefulness of potential drugs in cf and might prognosticate clinical course. in particular, combinations of protein biomarkers that can be obtained non-invasively offer great promise. the goal of this project is to determine whether protein biomarkers in blood can demonstrate a beneficial effect of treatment over two weeks. we intend to initially target an acute pulmonary exacerbation in cf because we know that subjects being treated with intravenous antibiotics and enhanced mucus clearance display clinical improvements within two weeks. we propose to prospectively collect blood samples from a large cohort of well-characterized cf persons serially during inpatient admissions for a pulmonary exacerbation and longitudinally during annual visits. through this proposal, we hope to identify a cf lung injury biomarker panel that increases in the setting of an acute pulmonary exacerbation and improves rapidly following intravenous antibiotic therapy. additionally, we will begin to explore whether this cf lung injury biomarker panel might also prognosticate clinical course including decline in pulmonary function. finally, this study will serve as an important source of blood samples that will be banked for future biomarker and therapeutic studies designed to benefit the entire cf community.


Eligibility criteria:
inclusion criteria: * diagnosis of cf as evidenced by a sweat chloride test \>60meq/l or by the presence of two known cf genetic mutations * male or female greater than or equal to 10 years of age * initiation of intravenous antibiotic therapy for a clinically diagnosed acute pulmonary exacerbation * ability to perform reproducible pulmonary function tests * willing to comply with the study procedures and willingness to provide written consent exclusion criteria: * presence of a condition or abnormality that, in the opinion of the principal investigator (pi), would compromise the safety of the patient or quality of the data

Keywords: cystic fibrosis pulmonary exacerbation biomarkers
long-term safety and efficacy of csl312 (garadacimab) in the prophylactic treatment of hereditary angioedema attacks

Conditions: Hereditary Angioedema

Summary: this phase 3b study will evaluate long-term safety and efficacy of csl312 (also known as garadacimab) when administered subcutaneously (sc)


Eligibility criteria:
inclusion criteria: * males and females aged ≥ 12 years * diagnosed with clinically confirmed c1-inh hae * experienced ≥ 3 hae attacks during the 3 months before screening * participated in the run-in period for at least 1 month (csl312-naïve subjects only) * experienced at least an average of 1 hae attack per month during the run-in period exclusion criteria: * concomitant diagnosis of another form of angioedema, such as idiopathic or acquired angioedema or recurrent angioedema associated with urticaria * use of c1-inh products, androgens, antifibrinolytics or other small molecule medications for routine prophylaxis against hae attacks at least 2 weeks before the first day of the run-in period * use of monoclonal antibodies such as lanadelumab (takhzyro®) 3 months before the first day of the run-in period. * female subjects use estrogen-containing oral contraceptives or hormone replacement therapy within 4 weeks prior to screening * female or male subjects who are fertile and sexually active not using or not willing to use an acceptable method of contraception to avoid pregnancy during the study and for 30 days after receipt of the last dose of csl312 * pregnant, breastfeeding, or not willing to cease breastfeeding
analgesic efficacy of oral glucose in preterm neonates during suctioning

Conditions: Analgesia

Summary: nasopharyngeal suctioning is a painful procedure that often becomes necessary in the care of preterm infants under cpap therapy several times a day. since the use of analgetic and sedative drugs is accompanied with multiple side effects these are usually being avoided. glucose 20% has been shown to have an analgesic effect when administered to preterm infants previous to some painful procedures (i.e blood sampling). in this clinical trial the efficacy of orally administered glucose 20% for relieving the procedural pain of nasopharyngeal suctioning is tested. the investigators' study has a cross-over design and is to include 40 patients.


Eligibility criteria:
inclusion criteria: * preterm newborns (\>1500g birth weight) up to a gestational age of 36+6 weeks * cpap respiratory therapy * parents' given written consent exclusion criteria: * diseases complicating neuromuscular evaluation. * drug abuse by the mother * administration of other analgetic or sedative drugs within the previous 48h. * participation in another interventional clinical trial within 4 weeks before the beginning of this trial.

Keywords: analgesia infant, premature glucose nasopharyngeal suctioning
effect of methylene blue on perioperative organ function in patients with obstructive jaundice

Conditions: Jaundice

Summary: increased production of vasodilating substances such as no plays an important role in the development of vasoplegic syndrome caused by obstructive jaundice.methylene blue plays a role in raising blood pressure by inhibiting the vasodilator nitric oxide (no)

the level of circulating hydrogen sulfide (h2s) in patients with obstructive jaundice is significantly increased. as a direct opener of katp channels in vivo, h2s also has diastolic peripheral vasculature . h2s participates in the occurrence of vasoplegic syndrome in patients with obstructive jaundice by interacting with no. however, it is unclear whether methylene blue can relieve vasoplegic syndrome in patients with obstructive jaundice by inhibiting the vasodilating effect of substances such as h2s and no. therefore, this clinical study intends to include patients with obstructive jaundice, using randomized, controlled, prospective study to explore the effect of methylene blue on the occurrence of vasoplegic syndrome, organ function and prognosis in patients with obstructive jaundice.

Eligibility criteria:
inclusion criteria: 1. age: 18\~70 years old; 2. asa grade i\~iii; 3. ability to comply with research protocols; 4. patients with obstructive jaundice: patients with total bilirubin greater than 50umol/l; 5. voluntarily participate in the study and sign the informed consent form. - exclusion criteria: 1. asa iv\~v grade; 2. women during lactation and pregnancy; 3. patients with severe heart disease or lung disease before surgery; 4. participating in other trials in the last 2 months; 5. those whose mental state cannot cooperate, who suffer from mental illness, have no self-control, and cannot express clearly; 6. those who refuse to sign the informed consent form. -
a study to evaluate the effect and safety of idoform plus on bowel side effects in healthy subjects treated with amoxicillin/ clavulanate

Conditions: Diarrhoea

Summary: it is hypothesized that idoform plus will recuce the occurence of gastrointestinal side effects related to the use of antibiotics


Eligibility criteria:
inclusion criteria: * healthy volunteers 18-70 years of age * subjects with normal gastrointestinal function * subjects willing to provide written informed consent exclusion criteria: * subjects receiving antibiotic treatment within three months prior to inclusion in the study * pregnancy or planned pregnancy * breast feeding * subjects who are allergic to beta-lactam antibiotics, amoxicillin / clavulanate or its components * subjects with known renal insufficiency * subjects using products containing probiotics, fibers and/or prebiotics * subjects using proton pump inhibitors * subjects using h2 antagonists * subjects using antacids frequently
a study to evaluate the safety and effectiveness of mirodenafil in korean patients with erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the purpose of this study is to evaluate the safety and effectiveness of mirodenafil in participants with erectile dysfunction.

this is a non randomized (the study medication is not assigned by chance), open-label (all participants and study staff know the identity of the treatment), multi-center, prospective (looking forward using observations collected following participant enrollment), and non-comparative study in which participants with erectile dysfunction will be observed to evaluate the safety and effectiveness of mirodenafil for 12 weeks. safety evaluations will include assessment of adverse events, and record of concomitant medications. the study will be conducted in korea.

Eligibility criteria:
inclusion criteria: * participants diagnosed with erectile dysfunction * participants prescribed mirodenafil on demand exclusion criteria: - participants who have administered mirodenafil for other than an approved indication

Keywords: erectile dysfunction mirodenafil bravonto
carbon dioxide insufflation versus conventional air insufflation

Conditions: Abdominal Pain

Summary: the safety and effectiveness of esophagogastroduodenoscopy and colonoscopy in the detection of gastrointestinal-tract pathology in children has been established during the last three decades. insufflation of the intestinal tract, usually with room air, is necessary to improve visualization during the procedure; however, air in the bowels can also result in abdominal distension and increased pain. this potential discomfort associated with upper endoscopy and colonoscopy may be an important barrier to patients undergoing this procedure. insufflation with carbon dioxide is another method used in endoscopic procedures for distention of the lumen and is currently used at the children's hospital of wisconsin based on provider preference. the aim of this study is to perform a randomized controlled trial comparing insufflation with room air to carbon dioxide in patients undergoing routine upper endoscopy and colonoscopy. the investigators primary outcome is measurement of patient comfort level as measured by pain scores during recovery. the investigators hypothesize that carbon dioxide insufflation during endoscopy and colonoscopy improves patient comfort level as compared with insufflation with room air. secondary outcome measures include changes in end tidal carbon dioxide, time to discharge, duration of colonoscopy and cecal intubation rate, changes in abdominal girth, rescue pain medications used during recovery and post-procedure events. this is a prospective randomized single-blinded study. the investigators will recruit consecutive patients, between the ages of 8 and 21 years, scheduled for elective outpatient upper endoscopy and colonoscopy at children's hospital of wisconsin from march 2015 until we reach target population numbers. the investigators will exclude all inpatients, non-english speaking patients, children under 8 years of age, patients undergoing colonic manometry studies, and patients with hemodynamic instability, gastrointestinal bleeding, acute abdomen, previous colectomy, oxygen-dependent pulmonary disease and obstructive sleep apnea requiring the use of continuous positive airway pressure device. on the basis of a computer-generated randomization scheme in a 1:1 ratio, patients will be assigned to receive room air or carbon dioxide for insufflation during colonoscopy. power calculation was done and determined that we will need to enroll 100 patients in each arm of the study. informed consent will be obtained from all patients by the endoscopist or gastrointestinal fellow.


Eligibility criteria:
inclusion criteria: * ages of 8 and 21 years * elective outpatient upper endoscopy and colonoscopy exclusion criteria: * inpatients * non-english speaking patients * children under 8 years of age * patients undergoing colonic manometry studies * patients with hemodynamic instability * gi bleeding * acute abdomen * previous colectomy * oxygen-dependent pulmonary disease and obstructive sleep apnea

Keywords: carbon dioxide air colonoscopy
relationship between serum β2-microglobulin and infiltration of cd8+ in the tumor tissue of hodgkin's lymphoma patients

Conditions: Hodgkin Lymphoma

Summary: in newly diagnosed hodgkin lymphoma patients, pre-treatment beta-2 microglobulin (b2m) levels will be measured. a thorough baseline assessment will be performed using ct imaging, and tumor tissue samples will be collected for immunohistochemical (ihc) analysis to quantify cd8+ cell infiltration. patients will be closely monitored throughout their treatment, with a follow-up ct scan at the end of therapy to evaluate therapeutic response. this study aims to investigate the correlation between pre-treatment b2m levels and cd8+ immune cell infiltration in tumor tissues, assessing their potential as predictive markers for chemotherapy response.


Eligibility criteria:
inclusion criteria: * newly diagnosed patients with hodgkin lymphoma * no prior history of malignancy * absence of primary or secondary immunodeficiencies exclusion criteria: * patients who have previously undergone treatment * patients with acute or chronic infections * patients with renal disorders * individuals with autoimmune diseases * hiv-positive patients

Keywords: serum beta-2 microglobulin, cd8+ cells, hodgkin lymphoma, predictive value, chemotherapy.
fixation of glenoid fractures

Conditions: Glenoid; Fracture

Summary: scapula fractures are uncommon but make up 3-5% of all shoulder girdle injuries. moreover, intraarticular glenoid fossa fractures represent only 1% of scapula fractures. they are frequently found with concomitant injuries to chest, head, brachial plexus and humerus. the glenoid is an oval shaped portion on the lateral border of the scapula that articulates with the circular rounded end of the humeral head. superiorly the glenoid is part of the superior shoulder suspensory complex (sssc) consisting of superior glenoid, coracoid process, coracoclavicular ligaments, distal end of the clavicle, acromioclavicular joint, coracoacromial ligament and acromial process. subsequently, stability of the shoulder is a complex mechanism in which muscles, ligamentous and capsular restraints, the labrum and joint vacuum, each play a role depending on position and activity. the history of patients with glenoid fractures will mostly consist of either shoulder dislocation or direct trauma to the humeral head. the affected arm is "pseudo-paralysed" and supported in adduction and internal rotation. because of a thick layer of soft tissue, only mild swelling and ecchymosis may be seen . for the diagnosis of scapular injuries x-rays are routinely taken , msct scanning , mri \& nerve conduction velocity may be done. main parameters defining operative treatment are instability, the articular surface fragment size and the degree of displacement. however, concomitant injuries (e.g. thorax, head, extremity fractures, plexus lesion), age, occupation, level of activity and dominance, play a key role in management.


Eligibility criteria:
inclusion criteria: * 1-fracture pattern: 1. all partial \& complete articular glenoid fractures: with non congruent articular surface; \>20° deviation in angle between the glenoid and lateral scapular rim compared to the anatomical angle. 2. all extra articular glenoid fractures: with \>20° deviation in angle between the glenoid and lateral scapular rim compared to the anatomical angle. 3. all extra articular glenoid fractures e \>20° difference in gpa compared to the gpa of the normal side. 4. fractures e an intra-articular gap or step-off of 4 to 10 mm or more. 5. if glenohumeral instability is present after dislocation. 2-age: skeletally mature patients (\>18-60y) exclusion criteria: * 1- fractures e an intra-articular gap or step-off \ 14. 4- associated neurovascular injury. 5- open fractures. 6- associated comorbidities e.g. (uncontrolled dm, renal impairment).

Keywords: internal fixation
japanese study evaluating the effects of telithromycin in children with community-acquired pneumonia

Conditions: Pneumonia

Summary: the primary objective is to assess the safety of telithromycin (hmr3647) 20 mg/kg qd for 5-7 days in children with community-acquired pneumonia (cap). secondary objectives are to assess pharmacokinetics, efficacy and acceptability of telithromycin 20 mg/kg qd for 5-7 days in children with cap.


Eligibility criteria:
inclusion criteria: * subjects who are weighing 40 kg or less. if female, premenarchal status is required. * subjects who are diagnosed with cap based on chest x-ray showing the presence of a new infiltrate, clinical symptoms, and laboratory findings. the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: community-acquired pneumonia cap children child